Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Laboratories has received approval to manufacture and market Coviro-LS kid and Coviro-LS kid DS, both double anti-retroviral and fixed dose combination, dispersible tablets for children, in India. The company has also filed the products with WHO Geneva for pre-qualification.
Subscribe to our email newsletter
The products are designed to deliver two Anti-Retroviral (ARV) drugs together in recommended strengths and simplify delivery of a more accurate treatment to children in resource poor settings. Both the approved formulations are reported to be scored dispersible tablets, and are pleasantly flavored.
While Coviro-LS kid contains Lamivudine 20mg and Stavudine 5mg, Coviro-LS kid DS contains the drugs in 40mg and 10mg strengths respectively. The products are bio-equivalent with the individual liquid formulations of the originators. The products are indicated for treatment of HIV infection in children.
Malvinder Mohan Singh, CEO and managing Director of Ranbaxy, said: “Ranbaxy is committed to develop innovative ARVs at affordable cost.”